Antengene Corp. Ltd. operates as a clinical-stage Asia-Pacific biopharmaceutical company, which engages in oncology medicines, R&D capabilities, and differentiated strategic approach to developing novel oncology therapies. It operates in the segments of the pharmaceutical, biotechnology and other related markets that address oncology diseases. The company was founded by Jian Ming Mei on August 28, 2018, and is headquartered in Shanghai, China.